Home › Targets › ALK5

ALK5 (1 companies · 2 programs)

Companies with an active program directed at ALK5.

Agomab Therapeutics NV AGMB

ontunisertib — Fibrostenotic Crohn's Disease Phase 2
AGMB-447 — Idiopathic Pulmonary Fibrosis Phase 1